Summit Therapeutics plc Aktie
Deine Einschätzung
Was spricht für und gegen Summit Therapeutics plc in den nächsten Jahren?
Pro
Kontra
Rendite von Summit Therapeutics plc im Vergleich
| Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
|---|---|---|---|---|---|---|---|
| Summit Therapeutics plc | - | - | - | - | - | - | - |
| Proteome Sciences | -7,41 % | 8,00 % | 3,85 % | -50,91 % | -53,45 % | -50,91 % | -43,75 % |
| Oxford BioMedica PLC | 1,46 % | 4,58 % | -2,84 % | 38,66 % | 34,31 % | 43,91 % | -42,32 % |
| Sareum Holdings plc | - | -6,67 % | 16,67 % | -48,67 % | -49,01 % | -77,68 % | - |
Kommentare
News
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run
Those who had the foresight to invest in Summit Therapeutics (NASDAQ: SMMT) and Madrigal Pharmaceuticals (NASDAQ: MDGL) three years ago are sitting pretty right now. Both companies have soared over
Why a $27 Million Buy Signals New Confidence in Weatherford Stock
Summit Street Capital Management established a new position in Weatherford International (NASDAQ:WFRD), adding 398,661 shares valued at an estimated $27.3 million during the third quarter, according
Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy?
On November 14, New York City-based Summit Street Capital Management disclosed a new position in Signet Jewelers (NYSE:SIG), acquiring 264,054 shares valued at $25.3 million, according to its latest



